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A B S T R A C T
The role of antiemetics is invaluable in allowing cancer
patients to complete, otherwise possibly intolerable,
chemotherapy. In the Perugia Consensus Conference it
was decided that the recommended antiemetic regimen
in the prevention of acute emesis induced by a single
high, low and repeated doses of cisplatin is a serotonin
receptor antagonist plus dexamethasone. 
We describe three testicular cancer patients who were cured
with chemotherapy but developed bilateral osteonecrosis of
the femoral head 17, 22 and 55 months after chemotherapy.
It is very likely that the dexamethasone used in the anti-
emetic drug regimen contributed to the development of
osteonecrosis in these patients. 
Osteonecrosis is a serious side effect of antiemetic treatment
with dexamethasone and this serious complication should
be incorporated in the current guidelines. Patients should
be informed about the risk of osteonecrosis when taking
dexamethasone as an antiemetic drug. A recommendation
to add corticosteroids to serotonin receptor antagonists only
after demonstrated nausea in chemotherapy regimes with
low-dose cisplatin (20 mg/m2) for five days seems justified. 
I N T R O D U C T I O N
The role of antiemetics is invaluable in allowing cancer
patients to complete, otherwise possibly intolerable,
chemotherapy. With the use of serotonin receptor an-
tagonists, a major breakthrough in antiemetic treatment,
namely complete protection against vomiting, was
achieved in 40 to 60%.1 Combination with dexamethasone
was shown to increase complete protection against vomiting
in 70 to 90% of patients.1 Nowadays, a serotonin receptor
antagonist plus dexamethasone is the regimen of choice
in the prevention of acute emesis induced by single high
and low and repeated doses of cisplatin.1 In this report we
present three patients who developed osteonecrosis of the
femoral heads after treatment with chemotherapy for
their testicular tumours.
C A S E  R E P O R T S
Patient A
A 29-year-old man with a previously unremarkable
medical history underwent a low anterior resection with
development of an anus praeter naturalis due to persistent
bleeding because of a tumour in the cavum douglasi. In
addition, a nephrostomy catheter in the right kidney was
inserted because of a hydronephrosis with rectal urine
loss due to a fistula. Pathological examination revealed a
seminoma stage II which originated from an intra-abdominal
testicle. Patient was treated with four cycles of BEP
(bleomycin 30 mg days 2, 8 and 15, etoposide 100 mg/m2
days 1 to 5, cisplatin 20 mg/m2 days 1 to 5) between
March and June 1991. After the second cycle the patient
developed an urogenital infection due to an obstructed
nephrostomy catheter. As antiemetics ondansetron 8 mg
intravenously was given once or twice daily on days 1 to 5
in addition to dexamethasone 10 mg intravenously once
daily on days 1 to 5. Thereafter, dexamethasone was
administered orally twice daily for four days in a dose of
6 mg for the first two and 3 mg for the second two days.
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Diazepam was added to the antiemetic regimen due to
persistent nausea and vomiting. In the first cycle the
patient received 20 mg of dexamethasone a day only once
because of vomiting. The total dose of steroids given was
equivalent to 2.21 g of prednisolone.2 In 1992 the fistula
was closed as well as the anus praeter naturalis. After
recovery from surgery the patient complained about erec-
tile dysfunction. There were no signs of persistent or
recurrent testicular cancer. In October 1995 the patient
complained about pain in the right hip. In January 1996,
bilateral osteonecrosis of the femoral heads was diagnosed
on conventional radiographs and MRI (55 months after
the end of chemotherapy). Initially a rotation osteotomy
according to Sugioka was performed on the right side. In
December 1998 treatment by bone impaction grafting
after removal of the osteonecrotic bone was performed on
the left side. Finally, in December 2000 the patient
underwent total hip replacement on the right side. 
Patient B
A 28-year-old man with stage IIa nonseminoma of the
right testis with rising serum tumour marker levels after
orchidectomy (good prognosis according to the International
Germ Cell Consensus Classification Group (IGCCCG)
classification) was treated with three cycles of BEP
(bleomycin 30 mg days 2,8 and 15, etoposide 100 mg/m2
days 1 to 5, cisplatin 20 mg/m2 days 1 to 5) and one cycle
of EP (same regimen without bleomycin) from November
1998 until January 1999. Nausea and vomiting were
controlled with a combination of ondansetron 8 mg and
dexamethasone 10 mg intravenously during the first five
days of the cycle. In addition dexamethasone was continued
for an additional two days at a dose of 3 mg twice daily.
Ondansetron 8 mg and dexamethasone 10 mg were also
given once just prior to the second gift of bleomycin (day
8) in the first cycle at the outpatient clinic to treat existing
nausea and vomiting. The total dose of steroids given to
the patient during treatment was equivalent to 1.61 g of
prednisolone.2 Treatment was unremarkable except for
one episode of leucopenic fever for which patient was
admitted to hospital for a short period. Postchemotherapy
restaging showed normal serum tumour markers in the
presence of residual disease on abdominal CT scan. In
March 1999, a retroperitoneal lymph node resection was
performed. Pathological examination revealed mature
teratoma. Thereafter, the patient has remained free of
recurrence. In December 2000 (22 months after comple-
tion of chemotherapy) the patient reported progressive
pain in his right hip. A radiograph of his right hip sug-
gested signs of osteonecrosis of the femoral head. An
MRI showed bilateral osteonecrosis of the femoral heads.
A bone scan scintigraphy excluded the presence of
metastatic disease. The bilateral femoral head necrosis
has so far been managed conservatively. 
Patient C
A 29-year-old man with stage IIA seminoma (IGCCCG:
good risk) was treated with three cycles of BEP (bleomycin
30 mg days 2, 8 and 15, etoposide 100 mg/m2 days 1 to 5,
cisplatin 20 mg/m2 days 1 to 5) given three-weekly
between August and October 1999. During the first five
days of every cycle, ondansetron 8 mg intravenously once
or twice daily and dexamethasone 10 mg intravenously
once daily were used as antiemetics. Dexamethasone was
continued orally for an additional two days at a dose of 3
mg twice daily. He received a dose of steroids equivalent
to 1.16 g of prednisolone over the three cycles of BEP
(using a conversion rate of 0.8 mg dexamethasone = 5 mg
prednisolone).2 He achieved a complete remission.
However, in March 2001 (17 months after completion of
chemotherapy) the patient complained about pain in the
left hip. Conventional radiographs as well as MRI (figure 1)
showed bilateral hip osteonecrosis. Medical history was
unremarkable with no prior steroid use. The BMI of
27.7 kg/m2 and the use of four units of alcohol a day were
the only other risk factors for avascular bone necrosis.
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Figures 1A (right hip) and B (left hip)
Coronal T1-weighted spin echo MR images of both hips
A serpentine line of very low signal intensity demarcates a large area of
low signal intensity in both femoral heads, representing osteonecrosis
(Association de la Recherche de la Circulation Osseuse Stage III).
Decompression surgery was applied to the right hip. The
left hip was treated conservatively.
D I S C U S S I O N
We report three patients who received chemotherapy
because of testicular cancer and who developed bilateral
osteonecrosis of the femoral heads. 
Osteonecrosis is not a specific disease entity but the final
common pathway of a number of conditions mostly leading
to an impairment of the blood supply to the bone.3
Diseases or conditions associated with or leading to
osteonecrosis are numerous (table 1).
The association between therapy for a malignancy and
the development of osteonecrosis of the femoral head
was first presented by Ihde and DeVita in 1975,4 a report
followed by many other reports of patients developing
osteonecrosis while being treated for Hodgkin’s disease or
lymphoma.5-7 In solid tumours, osteonecrosis is infrequently
reported. The publications concern testicular cancer2,8-10
and breast cancer11 and to a lesser extent endometrial cancer,11
ovarian cancer12 and prostate cancer. Despite the relative
rarity of testicular cancer, approximately 75% of the reported
cases in adults occurred in this group.8 Possible explanations
for this include the lack of recognition in other patient
groups and the specific effects of chemotherapy used to treat
testicular cancer. Various manifestations of late vascular
toxicity have been reported in survivors of testicular cancer.
The most well-recognised occurrence of chronic small-
vessel damage in patients treated with chemotherapy for
testicular cancer is Raynaud’s phenomenon, which occurs
in 23 to 43% of the patients.13 Damage to the autonomic
nervous system vessels caused by cisplatin or vinblastine
(both known to have neurotoxic side effects) that innervates
the peripheral smooth muscle is involved in the patho-
genesis of Raynaud’s phenomenon. Another example of
vascular toxicity is the capillary damage of the nailfold
which could be visualised by capillary microscopy, even in
asymptomatic patients treated with bleomycin.14 It can be
hypothesised that these vascular effects may contribute to
the development of osteonecrosis. Although age is not a
known risk factor for the development of osteonecrosis, it is
striking that osteonecrosis is also described more frequently
in Hodgkin patients who are generally of a similar young
age to testicular cancer patients. Young patients probably
have a more active lifestyle after treatment of their initial
disease. More and active weight bearing on the femoral
head will increase the risk of femoral head collapse leading
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Figures 1C (right hip) and D (left hip)
Coronal T2-weighted gradient echo, fat-suppressed MR
images of the same patient
The serpentine line (black; see arrow) is now surrounded by a narrow
zone of high signal intensity (oedema; white), known as ‘the double-
line sign’. This is considered highly specific for osteonecrosis.
Table 1
Conditions which can cause osteonecrosis of the femoral
head25,26
Trauma
Haemoglobinopathies: sickle-cell disease
Polycythaemia
Gaucher’s disease
Fabry’s disease
Caisson disease
Congenital and developmental conditions: Ehler-Danlos syndrome
Legg-Calvé-Perthes disease
Radiotherapy
Hypercortisolism: Cushing’s disease
Corticosteroid medications
Hyperparathyroidism
Excessive alcohol consumption
Coagulation disorders
Hyperlipidaemia
Vasculitis: systemic lupus erythematosus
Giant cell arthritis
Gout and hyperuricaemia
Diabetes mellitus
Pregnancy
to a higher degree of complaints. Based on three reports15,16
in which testicular cancer patients were followed after
chemotherapy, the crude incidence of osteonecrosis was
estimated at 1.5% (95% confidence interval 0.9-2.1%).
The incidence of asymptomatic osteonecrosis was 9%
(confidence interval: 2-20%) in a small group of patients
who previously received chemotherapy because of testicular
cancer.17 The incidence of symptomatic osteonecrosis was
3.8% in the same group. 
Corticosteroids, used as antiemetic therapy, are considered
to be the main cause of the development of osteonecrosis
in patients with solid tumours. In our report, all three
patients were treated with dexamethasone combined with
ondansetron as antiemetics. In the literature a few cases
have been reported in which osteonecrosis developed
after chemotherapy without previous administration of
dexamethasone.9,18 This finding suggests that cytotoxic
drugs contribute to the development of osteonecrosis. 
Several mechanisms are thought to play a role in the
development of corticosteroid-induced osteonecrosis.19
Firstly, the number of adipocites in the femoral head of
rabbits treated with corticosteroids is increased.20 This
increase in adipocites correlates with a higher intra-osseous
pressure in the femoral head, probably because the efferent
veins are compressed by the increased fat content and the
afferent arterial flow continues (Sterling mechanism).3
Furthermore, apoptosis of osteoblasts as well as of osteo-
clasts is increased with the use of corticosteroids.21
Finally, corticosteroids stimulate the differentiation of
bone marrow stem cells into adipocites.22 This leads to a
lower number of osteoblasts and therefore a decreased
repair and remodelling of osteonecrotic bone. 
There is no strict time-dose relationship between cortico-
steroids and the occurrence of osteonecrosis. Our patients
were on corticosteroids in prednisone-equivalent doses of
1.16 to 2.21 g. In the literature, prednisone-equivalent
doses ranging from 0.61 to 9.01 g have been reported.8
Although there are no studies that compare the risks of
short to medium-acting steroids, such as prednisone with
dexamethasone, it is likely that the latter places the patient
at a higher risk due to longer serum and biological half-life.
Winquist et al.8 reviewed 28 patients with osteonecrosis
after treatment for testicular cancer. In three patients
onset of osteonecrosis was acute while in 23 patients it was
delayed, by a mean of 26 months (range: 12-47 months),
after chemotherapy. In our three patients osteonecrosis
developed 17, 22 and 55 months after chemotherapy. 
Although the femoral head is affected most frequently
Harper et al.9 reported a patient with testicular cancer
who in addition to osteonecrosis of the femoral head also
suffered from osteonecrosis of the scaphoid and both
medial femoral condyles. In the study by Winquist et al.8
bilateral femoral head involvement was found in 70%.
In all our patients bilateral femoral head necrosis was
diagnosed. Control of emesis is important in protocol dose
adherence. In a double-blind study 531 patients were rando-
mised to one of four intravenous doses of dexamethasone
(4-8-12-20 mg) in combination with 8 mg of ondansetron.
Complete protection from vomiting was significantly
superior in patients who received 20 mg compared with
those who received 4 and 8 but not 12 mg.23 In a meta-
analysis of 3791 patients enrolled on 22 randomised trials
in which dexamethasone plus a serotonin antagonist was
compared with placebo treatment plus a serotonin anta-
gonist24 superiority of the dexamethasone arm was found.
Although these steroid-associated complications are
uncommon, they are devastating (sometimes even
requiring total hip replacement) especially in young
patients with potentially curable malignancy. The addition
of dexamethasone to the antiemetic regime is inevitable
to achieve optimal treatment. As no evident dose
response has been documented, the lowest effective dose
of dexamethasone should be used. 
In the American Society of Cancer Oncology guidelines
concerning antiemetics as well as in the Perugia
Consensus Conference regarding the optimal antiemetic
treatment1 osteonecrosis due to corticosteroids is not
mentioned. Although the development of osteonecrosis
in patients treated with chemotherapy is probably multi-
factorial, the likely contribution of corticosteroids should
have warranted the incorporation of this potential side
effect in the guidelines. Patients should be informed
about the increased risk of osteonecrosis when treated
with chemotherapy for which dexamethasone is used for
antiemetic treatment. In addition, osteonecrosis should
be included in the differential diagnosis of patients who
have been treated with chemotherapy and who present
with hip pain. At the onset of hip complaints in a patient
treated with corticosteroids, MRI should be performed if
plain X-rays show no significant signs of any disease. In
the late stages of osteonecrosis, radiographs and CT scan-
ning are sufficient to prove the existence and the exten-
sion of the disease; MRI is then no longer necessary.
Finally, a recommendation to add corticosteroids to sero-
tonin receptor antagonists only after demonstrated nau-
sea in chemotherapy regimes with low-dose cisplatin (20
mg/m2) for five days seems justified. 
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